MedTrace Logo

Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception

NCT02021097 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1008

Last updated 2013-12-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.

Conditions

  • Oral Contraceptive

Interventions

DRUG

Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg

Tablet, orally, opd

DRUG

Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg

Tablet, orally, opd

Sponsors & Collaborators

  • Regenex Pharmaceutical, China

    lead OTHER

Principal Investigators

  • Chengliang Xiong, Dr · Family Planning Research Institute of TJMC,HUST

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-02-28
Completion
2016-02-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021097 on ClinicalTrials.gov